Page Therapeutics, a biotech company focused on tackling metastatic cancer spread at its root, is pleased to announce the appointment of Meret Gaugler, PhD, as independent member of the Board of ...

STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...

Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the ...

The firm will use to funds to validate its CD123-targeted CAR T-cell therapies in acute myeloid leukemia in clinical studies.

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

O CEO da Nu Holdings, David Velez, disse que toda a América Latina está torcendo pelo sucesso do presidente Javier Milei na ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities ...